MVA-MERS-S Phase 1b Longterm Follow-up
The MVA-MERS-S-Phase1b trial was conducted as a two-centre, randomised, double-blind, placebo-controlled, Phase Ib study in healthy study subjects. The data were published in Lancet Infect D (
Raadsen et al
) in 2025. At the present time, a long-term follow-up (LTFU) is being conducted, with the aim of investigating the durability and persistence of MVA-based vaccine-induced immune responses. This investigation is being carried out in order to establish the results of the previous phase 1a trial. The initial two years of the LTFU were supported by the German Centre for Infection Research (DZIF).
Publication
Raadsen MP, Dahlke C, Fathi A, Hardtke S, Klüver M, Krähling V, Gerresheim GK, Mayer L, Mykytyn AZ, Weskamm LM, Zoran T, van Gorp ECM, Sutter G, Becker S, Haagmans BL, Addo MM; MVA-MERS-S_DF-1 Study group. Safety, immunogenicity, and optimal dosing of a modified vaccinia Ankara-based vaccine against MERS-CoV in healthy adults: a phase 1b, double-blind, randomised placebo-controlled clinical trial. Lancet Infect Dis. 2025 Feb;25(2):231-242. doi: 10.1016/S1473-3099(24)00423-7.